To assess the predictors and influence of resection margin
s and the role of neoadjuvant and adjuvant therapy on survival for a national cohort of patients with resected pancreatic cancer.
Using the National Cancer Data Base between 2004 and 2016, 56,532 patients were identified who underwent surgical resection for pancreatic adenocarcinoma. Univariate and multivariate models were employed to identify factors predicting R0/R1 resection and assess the impact on survival.
In total, 48,367 (85.6%) patients were found to have negative margins (R0) compared to 8165 (14.4%) who had microscopic residual tumor (R1). Factors predicting positive margin on univariate analysis included male gender, Medicare, advanced stage, moderately or poorly differentiated tumor, lymphovascular invasion, and tumors > 2 cm. Factors predicting R0 resection included receipt of neoadjuvant therapy and treatment at an Academic/Research Center. Following adjustment for other factors, margin status remained an independent predictor for overall survival (HR: 1.24; 95% CI 1.22–1.27, p < 0.001) (1-, 3-, and 5-year overall survival rates (R0: 77%, 37%, and 25% vs R1: 62%, 19%, and 10%).
A positive margin predicts a poorer survival than R0 resections regardless of stage and receipt of adjuvant therapy. Several modifiable factors significantly predict the likelihood of R0 resection including neoadjuvant treatment and treatment at Academic/Research Programs. Knowledge about these factors can help guide patient management by offering neoadjuvant treatment modalities at Academic as well as Community hospitals.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Siegel, R. L., Miller, K. D. & Jemal, A. Cancer statistics, 2020. CA Cancer J Clin 70, 7–30 (2020).
Morrison, A. H., Byrne, K. T. & Vonderheide, R. H. Immunotherapy and prevention of pancreatic cancer. Trends Cancer 4, 418–428 (2018).
Tummers, W. S. et al. Impact of resection margin status on recurrence and survival in pancreatic cancer surgery. Br. J. Surg. 106, 1055–1065 (2019).
Survival Rates for Pancreatic Cancer. at <https://www.cancer.org/cancer/pancreatic-cancer/detection-diagnosis-staging/survival-rates.html>
Baldwin, S. et al. Pancreatic cancer metastatic to a limited number of lymph nodes has no impact on outcome. HPB (Oxford) 18, 523–528 (2016).
Elshaer, M., Gravante, G., Kosmin, M., Riaz, A. & Al-Bahrani, A. A systematic review of the prognostic value of lymph node ratio, number of positive nodes and total nodes examined in pancreatic ductal adenocarcinoma. Ann R Coll Surg Engl 99, 101–106 (2017).
Ansari, D. et al. Relationship between tumour size and outcome in pancreatic ductal adenocarcinoma. Br. J. Surg. 104, 600–607 (2017).
Bilici, A. Prognostic factors related with survival in patients with pancreatic adenocarcinoma. World J. Gastroenterol. 20, 10802–10812 (2014).
Motoi, F. & Unno, M. Adjuvant and neoadjuvant treatment for pancreatic adenocarcinoma. Jpn. J. Clin. Oncol. (2020). doi:https://doi.org/10.1093/jjco/hyaa018
Ghaneh, P. et al. The impact of positive resection margins on survival and recurrence following resection and adjuvant chemotherapy for pancreatic ductal adenocarcinoma. Ann. Surg. 269, 520–529 (2019).
Acher, A. W., Bleicher, J., Cannon, A. & Scaife, C. Advances in surgery for pancreatic cancer. J. Gastrointest. Oncol. 9, 1037–1043 (2018).
Ocaña, J. et al. Relevance of positive resection margins in ductal pancreatic adenocarcinoma and prognostic factors. Cir Esp 98, 85–91 (2020).
Gnerlich, J. L. et al. Microscopic margins and patterns of treatment failure in resected pancreatic adenocarcinoma. Arch. Surg. 147, 753–760 (2012).
Verbeke, C. S. & Menon, K. V. Redefining resection margin status in pancreatic cancer. HPB (Oxford) 11, 282–289 (2009).
Seufferlein, T. & Ettrich, T. J. Treatment of pancreatic cancer-neoadjuvant treatment in resectable pancreatic cancer (PDAC). Transl. Gastroenterol. Hepatol. 4, 21 (2019).
Fenocchio, E. et al. Is there a standard adjuvant therapy for resected pancreatic cancer?. Cancers (Basel) 11, (2019).
Lambert, A. et al. An update on treatment options for pancreatic adenocarcinoma. Ther Adv Med Oncol 11, 1758835919875568 (2019).
Russo, S., Ammori, J., Eads, J. & Dorth, J. The role of neoadjuvant therapy in pancreatic cancer: a review. Future Oncol 12, 669–685 (2016).
Motoi, F. et al. Randomized phase II/III trial of neoadjuvant chemotherapy with gemcitabine and S-1 versus upfront surgery for resectable pancreatic cancer (Prep-02/JSAP05). Jpn. J. Clin. Oncol. 49, 190–194 (2019).
Datta, S. K. et al. Survival outcomes between surgery with adjuvant therapy compared to neoadjuvant therapy with surgery in stage I pancreatic adenocarcinoma: Results from a large national cancer database. J. Clin. Oncol. 37, 335–335 (2019).
White, M. G. et al. A tale of two cancers: traveling to treat pancreatic and thyroid cancer. J. Am. Coll. Surg. 225, 125–136.e6 (2017).
Søreide, J. A., Sandvik, O. M. & Søreide, K. Improving pancreas surgery over time: Performance factors related to transition of care and patient volume. Int J Surg 32, 116–122 (2016).
Raoof, M. et al. Centralization of pancreatic cancer surgery: travel distances and disparities. J. Am. Coll. Surg. 223, e166 (2016).
Fong, Y., Gonen, M., Rubin, D., Radzyner, M. & Brennan, M. F. Long-term survival is superior after resection for cancer in high-volume centers. Ann. Surg. 242, 540–4; discussion 544 (2005).
Strobel, O. et al. Pancreatic Cancer Surgery: The New R-status Counts. Ann. Surg. 265, 565–573 (2017).
Conflict of interest statement
All authors certify that they have NO affiliations with or involvement in any organization or entity with any financial interest (such as honoraria; educational grants; participation in speakers’ bureaus; membership, employment, consultancies, stock ownership, or other equity interest; and expert testimony or patent-licensing arrangements), or non-financial interest (such as personal or professional relationships, affiliations, knowledge or beliefs) in the subject matter or materials discussed in this manuscript. The University of Pittsburgh holds a Physician-Scientist Institutional Award from the Burroughs Wellcome Fund: C.K. S.K.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Kaltenmeier, C., Nassour, I., Hoehn, R.S. et al. Impact of Resection Margin Status in Patients with Pancreatic Cancer: a National Cohort Study. J Gastrointest Surg (2020). https://doi.org/10.1007/s11605-020-04870-6
- Margin status
- predictors of R1 resection
- pancreatic cancer